Gujarat Themis Biosyn Limited

BSE:506879 Stock Report

Market Cap: ₹33.2b

Gujarat Themis Biosyn Past Earnings Performance

Past criteria checks 2/6

Gujarat Themis Biosyn has been growing earnings at an average annual rate of 20.8%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 17.3% per year. Gujarat Themis Biosyn's return on equity is 23.6%, and it has net margins of 34.1%.

Key information

20.8%

Earnings growth rate

20.8%

EPS growth rate

Pharmaceuticals Industry Growth17.5%
Revenue growth rate17.3%
Return on equity23.6%
Net Margin34.1%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Gujarat Themis Biosyn makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

BSE:506879 Revenue, expenses and earnings (INR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,5435271240
30 Jun 241,5915471280
31 Mar 241,6985921180
31 Dec 231,563550970
30 Sep 231,456518900
30 Jun 231,530579980
31 Mar 231,484580940
31 Dec 221,496561740
30 Sep 221,400534730
30 Jun 221,274485810
31 Mar 221,149436720
31 Dec 211,094396760
30 Sep 211,152400750
30 Jun 211,073375780
31 Mar 21906302740
31 Dec 20936353720
30 Sep 20998376720
30 Jun 20891278760
31 Mar 20851237660
31 Dec 19691152620
30 Sep 1948367560
30 Jun 1942465550
31 Mar 1941064530
31 Dec 1840649520
30 Sep 1840747530
30 Jun 1839743530
31 Mar 1838839450
31 Dec 1739339470
30 Sep 1737940460
30 Jun 1736739460
31 Mar 1735744450
31 Dec 1633544430
30 Sep 1632943440
30 Jun 1632745480
31 Mar 1632646440
31 Dec 1532441570
30 Sep 1532546550
30 Jun 1532146540
31 Mar 1531446420
31 Dec 1430751510
30 Sep 1430148510
30 Jun 1430249430
31 Mar 1430245510
31 Dec 1330331590

Quality Earnings: 506879 has a high level of non-cash earnings.

Growing Profit Margin: 506879's current net profit margins (34.1%) are lower than last year (35.6%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: 506879's earnings have grown significantly by 20.8% per year over the past 5 years.

Accelerating Growth: 506879's earnings growth over the past year (1.8%) is below its 5-year average (20.8% per year).

Earnings vs Industry: 506879 earnings growth over the past year (1.8%) did not outperform the Pharmaceuticals industry 20.5%.

Return on Equity

High ROE: 506879's Return on Equity (23.6%) is considered high.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/28 16:36
End of Day Share Price 2024/12/27 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Gujarat Themis Biosyn Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Anil BurraFirstCall Research